Literature DB >> 21070754

Hemodialysis vascular access thrombosis: The role of factor V Leiden, prothrombin gene mutation and ABO blood groups.

Danyelle R A Rios1, Ana P Fernandes, Maria G Carvalho, Roberta C Figueiredo, Daniela A M Guimarães, Daniberg R Reis, Ana C Simões e Silva, Karina B Gomes, Luci M S Dusse.   

Abstract

BACKGROUND: Vascular access thrombosis increases morbidity in hemodialysis (HD) patients. The aim of this study was to investigate the association between HD vascular access thrombosis and mutations in the prothrombin and factor V Leiden (FV) genes and ABO blood system.
METHODS: This cross-sectional study included 195 patients with end stage renal disease (ESRD) on HD for more than six months. HD patients were allocated into two groups according to the occurrence (cases, N=46) or not (controls, N=149) of previous vascular access thrombosis. FV and prothrombin gene mutations were investigated by polymerase chain reaction and ABO blood group phenotyping was performed by the indirect technique. Univariate analysis detected the variables with a trend to be associated with thrombosis and was followed by multivariate analysis to define independent predictors of vascular access thrombosis.
RESULTS: FV Leiden mutation and ABO blood group were not associated with vascular access thrombosis, whereas G20210A mutation in the prothrombin gene was significantly higher in patients with vascular access thrombosis and independently associated with this complication (OR=12.0; CI 95%=1.8-83.5; p=0.012).
CONCLUSIONS: G20210A mutation emerges as an important genetic factor predisposing to vascular access thrombosis. The definition of risk factors for thrombosis will certainly enable a rational approach for HD patients. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070754     DOI: 10.1016/j.cca.2010.11.002

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.

Authors:  Danyelle R A Rios; Maria G Carvalho; Roberta C Figueiredo; Cláudia N Ferreira; Valério L Rodrigues; Regina A Souza; Ana C Simões e Silva; Ana Paula Fernandes; Karina B Gomes; Luci M S Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

3.  Plasma von Willebrand Factor and a Disintegrin and Metalloproteinase with Eight Thrombospondin-type 1 Motif Levels in Hemodialysis Patients: Relation to Vascular Access Thrombosis.

Authors:  Khaled M A Elzorkany; Belal A M Montaser; Sally M El-Hefnawy
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

4.  Hereditary thrombophilia and thrombosis of tunneled hemodialysis catheters: A single center study.

Authors:  Farzad Kakaei; Saba Mirabolfathi; Negin Yavari; Mohammad Reza Ardalan; Mehrdad Mozafar; Sina Zarrintan
Journal:  J Cardiovasc Thorac Res       Date:  2021-01-19

5.  Thrombophilic risk factors and ABO blood group profile for arteriovenous access failure in end stage kidney disease patients: a single-center experience.

Authors:  Sunnesh Reddy Anapalli; Harini Devi N; Pvgk Sarma; Lokanathan Srikanth; Siva Kumar V
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

Review 6.  The molecular mechanisms of hemodialysis vascular access failure.

Authors:  Akshaar Brahmbhatt; Andrea Remuzzi; Marco Franzoni; Sanjay Misra
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.